Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with documented efficacy in non-small-cell lung cancer. However, in most cases, patients develop resistance to this treatment by mechanisms that are not clear in half of the cases. Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies.